scispace - formally typeset
A

Agata Braniewska

Researcher at Medical University of Warsaw

Publications -  9
Citations -  514

Agata Braniewska is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 4, co-authored 9 publications receiving 323 citations.

Papers
More filters
Journal ArticleDOI

MicroRNA in cardiovascular biology and disease.

TL;DR: In this paper, a review discusses emerging functions of miRNAs in cardiogenesis, heart regeneration and the pathophysiology of cardiovascular diseases, including myocardial infarction, hypertrophy, fibrosis, heart failure, arrhythmia, inflammation and atherosclerosis.
Journal ArticleDOI

Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages

TL;DR: The phenotype and functional stability of the RAW 264.7 cell line is investigated and it is found that the phenotype (expression of particular macrophage-characteristic genes and surface markers) and functional characteristics (phagocytosis and NO production) of the cell line remains stable through passages.
Journal ArticleDOI

Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment

TL;DR: It is concluded that administration of agonistic anti-CD200R improves the antitumor effects of TLR7 signaling and changes the local tumor microenvironment, which becomes less supportive of tumor progression.
Journal ArticleDOI

Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy.

TL;DR: It is found that the expression of IDO, elevated after PDT, affects the polarization of T regulatory cells and influences the innate immune response, and overcoming IDO-induced immunosuppressive mechanisms after PDT can be beneficial or can lead to a systemic toxic reaction.
Journal ArticleDOI

The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.

TL;DR: It is concluded that blockade of the endogenous ligand CD200 prevented the tumorigenic effect of CD200R-expressing myeloid cells in the tumor microenvironment, whereas agonistic anti-CD200R has no effect on tumor development.